AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16271721 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ergometrine
Number of subjects: 0
Study 16271721 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin
Number of subjects: 0
Study 12840615 — intervention group
Group type: EXPERIMENTAL
Intervention: High spousal solicitousness in males
Number of subjects: 327
Study 12840615 — intervention group
Group type: EXPERIMENTAL
Intervention: High spousal solicitousness in females
Number of subjects: 327
Study 12840615 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal solicitousness in both genders
Number of subjects: 327
Study 10374157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified (HSM) intraocular lenses (IOLs)
Number of subjects: 90
Study 10374157 — intervention group
Group type: COMPARATOR
Intervention: Unmodified poly(methyl methacrylate) (PMMA) IOL
Number of subjects: 90
Study 8894357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for 4 weeks (patients with PUD)
Number of subjects: 124
Study 8894357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for 4 weeks (patients without PUD)
Number of subjects: 124
Study 8894357 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks (patients without PUD)
Number of subjects: 124
Study 8894357 — intervention group
Group type: COMPARATOR
Intervention: Minor mucosal lesions (Ranitidine vs Placebo)
Number of subjects: 124
Study 1814841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 50 mg
Number of subjects: 32
Study 1814841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 100 mg
Number of subjects: 32
Study 1814841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg
Number of subjects: 32
Study 1814841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg
Number of subjects: 32
Study 1814841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 50 to 200 mg
Number of subjects: 32
Study 1814841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6402540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 11
Study 6402540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30946953 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS (high-frequency, low-intensity)
Number of subjects: 80
Study 30946953 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS (low-frequency, high-intensity)
Number of subjects: 80
Study 30946953 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 80
Study 28864706 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating with reset contingency management (CM) as an adjunct to standard smoking cessation treatment over a 5-week period
Number of subjects: 40
Study 28864706 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation treatment
Number of subjects: 40
Study 26530856 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive interventions (surgery, embolization, radiation therapy, alone or combined)
Number of subjects: 2000
Study 26530856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical or pre-radiation embolization
Number of subjects: 2000
Study 26530856 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 2000
Study 26530856 — intervention group
Group type: COMPARATOR
Intervention: No embolization
Number of subjects: 2000
Study 23374528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (F)
Number of subjects: 10
Study 23374528 — intervention group
Group type: COMPARATOR
Intervention: Sutures (S)
Number of subjects: 10
Study 21126997 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 27
Study 20137481 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine treatment for 8 weeks
Number of subjects: 50
Study 20137481 — intervention group
Group type: EXPERIMENTAL
Intervention: TRD patients
Number of subjects: 50
Study 20137481 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRD patients
Number of subjects: 50
Study 17519218 — intervention group
Group type: EXPERIMENTAL
Intervention: TW UV‐B
Number of subjects: 1241
Study 17519218 — intervention group
Group type: EXPERIMENTAL
Intervention: SW UV‐B
Number of subjects: 1241
Study 17519218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath PUVA
Number of subjects: 1241
Study 12911449 — intervention group
Group type: EXPERIMENTAL
Intervention: Kliogest
Number of subjects: 120
Study 10678578 — intervention group
Group type: EXPERIMENTAL
Intervention: Microspot CO2 laser excision
Number of subjects: 37
Study 10678578 — intervention group
Group type: COMPARATOR
Intervention: Microdissection
Number of subjects: 37
Study 9070591 — intervention group
Group type: EXPERIMENTAL
Intervention: TPM 1,000 mg/day
Number of subjects: 48
Study 9070591 — intervention group
Group type: COMPARATOR
Intervention: TPM 100 mg/day
Number of subjects: 48
Study 8444274 — intervention group
Group type: COMPARATOR
Intervention: Jejunal infusion of 1.3 kcal min‐1 (5.5 kJ min‐1)
Number of subjects: 6
Study 8444274 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal infusion of 3.3 kcal min‐1 (14.0 kJ min‐1)
Number of subjects: 6
Study 8444274 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 3098132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin ointment applied to the forehead 12 minutes prior to intubation
Number of subjects: 56
Study 3098132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin ointment)
Number of subjects: 56
Study 31757717 — intervention group
Group type: COMPARATOR
Intervention: Sutures plus chlorhexidine gluconate (CHG) dressing (standard care)
Number of subjects: 121
Study 31757717 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus tissue adhesive (TA)
Number of subjects: 121
Study 31757717 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sutureless stabilisation devices (SSD) plus CHG dressing
Number of subjects: 121
Study 31757717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures, CHG disc plus integrated securement dressing (ISD)
Number of subjects: 121
Study 30453487 — intervention group
Group type: EXPERIMENTAL
Intervention: Test yogurt enriched with Lactococcus lactis 11/19-B1 and Bifidobacterium lactis BB-12, 80 g daily for 8 weeks
Number of subjects: 76
Study 30453487 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt fermented with Streptococcus thermophiles, Lactobacillus delbrueckii subspecies bulgaricus, and Lactobacillus acidophilus, 80 g daily for 8 weeks
Number of subjects: 76
Study 26723083 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 4.5 mg/kg intravenously over 3 days (0.5 mg/kg 2 days before transplantation, 2.0 mg/kg 1 day before, and 2.0 mg/kg 1 day after)
Number of subjects: 203
Study 26723083 — intervention group
Group type: COMPARATOR
Intervention: No anti-thymocyte globulin (no ATG)
Number of subjects: 203
Study 26723083 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 203
Study 24113319 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (6 months of supervised exercise followed by 6 months of home-based maintenance)
Number of subjects: 100
Study 24113319 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 100
Study 24113319 — intervention group
Group type: COMPARATOR
Intervention: Printed educational material about physical activity (control group)
Number of subjects: 100
Study 22749600 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine
Number of subjects: 112
Study 22749600 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study 20400411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc (VCV) 5, 10, or 15 mg
Number of subjects: 118
Study 20400411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 18324565 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers aged 50+
Number of subjects: 0
Study 18324565 — intervention group
Group type: COMPARATOR
Intervention: Smokers aged <50
Number of subjects: 0
Study 18324565 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 50+
Number of subjects: 0
Study 18324565 — intervention group
Group type: COMPARATOR
Intervention: Men aged <50
Number of subjects: 0
Study 18324565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 0
Study 18324565 — intervention group
Group type: EXPERIMENTAL
Intervention: Older smokers
Number of subjects: 0
Study 15973115 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA 500 mg suppository (Canasa; Axcan Pharma) BID
Number of subjects: 99
Study 15973115 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA 1 g at bedtime (HS)
Number of subjects: 99
Study 15973115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study 14636777 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic treatment for transitory cognitive impairment (TCI)
Number of subjects: 0
Study 14636777 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10610747 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine with alcohol
Number of subjects: 12
Study 10610747 — intervention group
Group type: EXPERIMENTAL
Intervention: De-alcoholized red wine
Number of subjects: 12
Study 10610747 — intervention group
Group type: COMPARATOR
Intervention: Control (before drinking)
Number of subjects: 12
Study 8633817 — intervention group
Group type: EXPERIMENTAL
Intervention: 3600 mg saquinavir per day
Number of subjects: 40
Study 8633817 — intervention group
Group type: EXPERIMENTAL
Intervention: 7200 mg saquinavir per day
Number of subjects: 40
Study 9259838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin replacement therapy
Number of subjects: 132
Study 9259838 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 132
Study 6414283 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial starch blocker
Number of subjects: 6
Study 6414283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31443654 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (20 mg/kg)
Number of subjects: 30
Study 31443654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30119697 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training (60-80% of heart rate reserve)
Number of subjects: 22
Study 30119697 — intervention group
Group type: COMPARATOR
Intervention: Walking outside (control group, below 40% of heart rate reserve)
Number of subjects: 22
Study 30119697 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training
Number of subjects: 22
Study 30119697 — intervention group
Group type: COMPARATOR
Intervention: Walking outside (control group)
Number of subjects: 22
Study 27267950 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (6h/night)
Number of subjects: 34
Study 27267950 — intervention group
Group type: COMPARATOR
Intervention: Long sleep (9h/night)
Number of subjects: 34
Study 24708443 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral corticosteroids (LTOC)
Number of subjects: 444
Study 21643774 — intervention group
Group type: EXPERIMENTAL
Intervention: V0355 (80 mg Fe/day)
Number of subjects: 399
Study 21643774 — intervention group
Group type: COMPARATOR
Intervention: Ferrograd® (105 mg Fe/day)
Number of subjects: 399
Study 21643774 — intervention group
Group type: EXPERIMENTAL
Intervention: V0355
Number of subjects: 399
Study 21643774 — intervention group
Group type: COMPARATOR
Intervention: Ferrograd®
Number of subjects: 399
Study 20006642 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help plus telephone counseling (SH+C)
Number of subjects: 2470
Study 20006642 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 2470
Study 17363762 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-reactivity measures
Number of subjects: 0
Study 17363762 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS-reactivity measures
Number of subjects: 0
Study 17363762 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity measures
Number of subjects: 0
Study 16326661 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia support program delivered over the Internet (Caregiver's Friend: Dealing with Dementia)
Number of subjects: 299
Study 16326661 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 299
Study 11914399 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery (unilateral posterior pallidotomy)
Number of subjects: 33
Study 11914399 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery (unilateral posterior pallidotomy) with left lesions
Number of subjects: 33
Study 11914399 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 33
Study 11914399 — intervention group
Group type: EXPERIMENTAL
Intervention: History of depression
Number of subjects: 33
Study 9808644 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mL/d of apple juice containing 5 g of gum arabic and pectin (4:1 ratio)
Number of subjects: 110
Study 9808644 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mL/d of apple juice containing 9 g of gum arabic and pectin (4:1 ratio)
Number of subjects: 110
Study 9808644 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mL/d of apple juice containing 15 g of gum arabic and pectin (4:1 ratio)
Number of subjects: 110
Study 9808644 — intervention group
Group type: COMPARATOR
Intervention: 720 mL/d of apple juice (control)
Number of subjects: 110
Study 9808644 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout phase (apple juice only)
Number of subjects: 110
Study 7631621 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (2.5 to 10 mg) with 6.25 mg of hydrochlorothiazide (HCTZ)
Number of subjects: 218
Study 7631621 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine (2.5 to 10 mg)
Number of subjects: 218
Study 7631621 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (5 to 20 mg)
Number of subjects: 218
Study 2360544 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (200 micrograms/d for 3 weeks)
Number of subjects: 0
Study 2360544 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic selenite (200 micrograms/d for 3 weeks)
Number of subjects: 0
Study 2360544 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium from deep body pools
Number of subjects: 0
Study 7346529 — intervention group
Group type: EXPERIMENTAL
Intervention: H-1 antagonist hydroxyzine
Number of subjects: 13
Study 7346529 — intervention group
Group type: COMPARATOR
Intervention: H-2 antagonist cimetidine
Number of subjects: 13
Study 7346529 — intervention group
Group type: COMPARATOR
Intervention: Combination of H-1 and H-2 antagonists
Number of subjects: 13
Study 7346529 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine alone
Number of subjects: 13
Study 7346529 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 13
Study 7346529 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine plus cimetidine
Number of subjects: 13
Study 31305270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (840 mg loading dose followed by 420 mg maintenance doses every 3 weeks)
Number of subjects: 15
Study 31305270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (in combination with trastuzumab)
Number of subjects: 15
Study 31305270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 15
Study 27025843 — intervention group
Group type: EXPERIMENTAL
Intervention: IV aminophylline (100 mg administered over 30-60 seconds)
Number of subjects: 241
Study 27025843 — intervention group
Group type: EXPERIMENTAL
Intervention: IV caffeine citrate (60 mg infused over 3-5 minutes)
Number of subjects: 241
Study 27025843 — intervention group
Group type: EXPERIMENTAL
Intervention: PO caffeine (as coffee or diet cola)
Number of subjects: 241
Study 27025843 — intervention group
Group type: EXPERIMENTAL
Intervention: PO caffeine
Number of subjects: 241
Study 27025843 — intervention group
Group type: EXPERIMENTAL
Intervention: IV aminophylline and IV caffeine
Number of subjects: 241
Study 27132456 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incision combined with percutaneous tracheostomy (small puncture incision group, n = 25)
Number of subjects: 57
Study 27132456 — intervention group
Group type: COMPARATOR
Intervention: Conventional tracheostomy (control group, n = 32)
Number of subjects: 57
Study 24647226 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel disposable circumcision device (Device Group)
Number of subjects: 120
Study 24647226 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection technique (Control Group)
Number of subjects: 120
Study 24647226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 22730040 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus dextromethorphan (Risp+ DM)
Number of subjects: 95
Study 22730040 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (Risp) only
Number of subjects: 95
Study 19786379 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg lutein/d
Number of subjects: 37
Study 19786379 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg lutein/d
Number of subjects: 37
Study 19786379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 17538165 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine (GemCap) - oral capecitabine 650 mg/m2 twice daily on days 1 to 14 plus Gem 1,000 mg/m2 by 30‐minute infusion on days 1 and 8 every 3 weeks
Number of subjects: 319
Study 17538165 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (Gem) - 1,000 mg/m2 by 30‐minute infusion weekly for 7 weeks, followed by a 1‐week break, and then weekly for 3 weeks every 4 weeks
Number of subjects: 319
Study 17538165 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine (GemCap) in patients with good Karnofsky performance score (KPS)
Number of subjects: 319
Study 17538165 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (Gem) in patients with good Karnofsky performance score (KPS)
Number of subjects: 319
Study 17538165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GemCap and Gem
Number of subjects: 319
Study 16566943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse low doses of methylprednisolone (250 mg given twice IV)
Number of subjects: 60
Study 16566943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14527736 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antihistamines with combined topical corticosteroid treatment (Group 1)
Number of subjects: 32
Study 14527736 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antihistamines without steroid treatment (Group 2)
Number of subjects: 32
Study 14527736 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 32
Study 14527736 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antihistamines (both groups)
Number of subjects: 32
Study 10790990 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Stimulants (MPH, DEX, pemoline)
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (desipramine, imipramine)
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Combination therapies (stimulant or nondrug intervention)
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Stimulants vs. placebo
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Adverse effects of drug therapy
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Long-term therapy (> or = 12 weeks)
Number of subjects: 78
Study 10790990 — intervention group
Group type: COMPARATOR
Intervention: Academic performance with stimulants
Number of subjects: 78
Study 8932964 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antidepressants (imipramine, fluoxetine, sertraline)
Number of subjects: 0
Study 8932964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0
Study 8932964 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 0
Study 8932964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1989742 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia combined with light sedation (midazolam 0.1 mg.kg‐1 and alfentanil 0 micrograms.kg‐1)
Number of subjects: 28
Study 1989742 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (propofol 2.5 mg.kg‐1, then 9 mg.kg‐1.hr‐1 and alfentanil 30 micrograms.kg‐1, then 15 micrograms.kg‐1)
Number of subjects: 28
Study 6307340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymoral with Polyglycolic acid sutures
Number of subjects: 190
Study 6307340 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Polyglycolic acid sutures
Number of subjects: 190
Study 6307340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymoral with catgut sutures
Number of subjects: 190
Study 6307340 — intervention group
Group type: COMPARATOR
Intervention: Placebo with catgut sutures
Number of subjects: 190
Study 31313021 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (N = 18)
Number of subjects: 39
Study 31313021 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (N = 21)
Number of subjects: 39
Study 31313021 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 39
Study 28777246 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw clenching
Number of subjects: 36
Study 28777246 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw clenching with mouthpiece
Number of subjects: 36
Study 28777246 — intervention group
Group type: COMPARATOR
Intervention: Control (no jaw clenching)
Number of subjects: 36